Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
$0.01
$0.00
$0.00
$0.05
$663K1.892,949 shsN/A
Kaya Holdings, Inc. stock logo
KAYS
Kaya
$0.03
$0.04
$0.03
$0.09
$430K0.583,017 shs741 shs
Reliv' International, Inc. stock logo
RELV
Reliv' International
$3.85
$3.51
$2.50
$4.42
$6.72M-0.123,200 shsN/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
$0.22
$0.22
$0.08
$0.34
$56.90M2.65,474 shsN/A
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
0.00%+257.14%+185.71%+733.33%-80.00%
Kaya Holdings, Inc. stock logo
KAYS
Kaya
+4.29%-5.81%-18.89%-32.87%-46.52%
Reliv' International, Inc. stock logo
RELV
Reliv' International
0.00%+1.32%-3.75%-2.04%+5.48%
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/AN/AN/AN/AN/AN/AN/AN/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
N/AN/AN/AN/AN/AN/AN/AN/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
N/AN/AN/AN/A
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/AN/AN/AN/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
N/AN/AN/AN/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
$1.56M0.43N/AN/AN/A
Kaya Holdings, Inc. stock logo
KAYS
Kaya
$200K2.15$0.13 per share0.22($1.07) per share-0.03
Reliv' International, Inc. stock logo
RELV
Reliv' International
$35.06M0.19$0.09 per share44.53$6.36 per share0.61
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
$7.38M7.71N/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
-$880KN/A0.00N/AN/AN/AN/AN/A
Kaya Holdings, Inc. stock logo
KAYS
Kaya
$1.61M-$0.02N/AN/A821.43%-9.57%638.26%4/26/2024 (Estimated)
Reliv' International, Inc. stock logo
RELV
Reliv' International
-$440KN/AN/AN/A-0.61%-1.89%-1.31%N/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
-$18.79M-$0.08N/AN/A-254.66%-346.72%-94.54%N/A

Latest TRLPF, ACUR, RELV, and KAYS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/16/2024Q4 2023
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/A$0.01+$0.01$0.01N/A$0.03 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
N/AN/AN/AN/AN/A
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/AN/AN/AN/AN/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
N/AN/AN/AN/AN/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
N/AN/AN/A
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/A
0.01
0.01
Reliv' International, Inc. stock logo
RELV
Reliv' International
0.05
1.70
1.04
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
0.64
1.35
0.90

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
N/A
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
7.95%
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
0.02%

Insider Ownership

CompanyInsider Ownership
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
20.20%
Kaya Holdings, Inc. stock logo
KAYS
Kaya
23.52%
Reliv' International, Inc. stock logo
RELV
Reliv' International
31.18%
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
966.35 million52.95 millionNot Optionable
Kaya Holdings, Inc. stock logo
KAYS
Kaya
414.72 million11.26 millionNot Optionable
Reliv' International, Inc. stock logo
RELV
Reliv' International
911.75 millionN/ANot Optionable
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
29258.62 millionN/ANot Optionable

TRLPF, ACUR, RELV, and KAYS Headlines

SourceHeadline
Takeda Pharmaceutical Co. Ltd. ADRTakeda Pharmaceutical Co. Ltd. ADR
wsj.com - February 8 at 10:03 AM
Other OTC Pharmaceuticals - LithuaniaOther OTC Pharmaceuticals - Lithuania
statista.com - September 17 at 1:59 AM
2023 A Big Year For Testosterone: AbbVie And ANI Pharmaceuticals Best Positioned To Benefit2023 A Big Year For Testosterone: AbbVie And ANI Pharmaceuticals Best Positioned To Benefit
seekingalpha.com - January 1 at 9:14 AM
Acerus Reports Second Quarter 2022 Financial ResultsAcerus Reports Second Quarter 2022 Financial Results
financialpost.com - August 9 at 7:47 AM
Acerus Reports Fourth Quarter and Full Year 2021 Financial ResultsAcerus Reports Fourth Quarter and Full Year 2021 Financial Results
financialpost.com - March 15 at 7:47 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Acura Pharmaceuticals logo

Acura Pharmaceuticals

OTCMKTS:ACUR
Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc. and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was formerly known as Halsey Drug Co., Inc. The company was incorporated in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals, Inc. operates as a subsidiary of Abuse Deterrent Pharma, LLC.
Kaya logo

Kaya

OTCMKTS:KAYS
Kaya Holdings, Inc., a vertically integrated legal cannabis enterprise, produces, distributes, and/or sells a range of cannabis products primarily in the United States. The company offers flower, oils, vape cartridges and cannabis infused confections, baked goods, and beverages. It also operates retail outlets under the Kaya Shack brand name, as well as offers strain specific cannabis cigarettes under the Kaya Buddies name, and strains of cannabis under the Kaya Farms name. In addition, the company provides standing display cases with cannabis intended glassware under the Really Happy Glass brand; and t-shirt designs under the Kaya Gear brand name. The company was formerly known as Alternative Fuels America, Inc. and changed its name to Kaya Holdings, Inc. in April 2015. Kaya Holdings, Inc. was incorporated in 1993 and is headquartered in Fort Lauderdale, Florida.
Reliv

Reliv' International

NASDAQ:RELV
Reliv' International, Inc. develops and markets nutritional supplements that address basic nutrition, specific wellness needs, weight management, and sports nutrition. The company's basic nutritional supplements are formulated to provide a balanced and complete level of supplementation for the consumer. Its principal products include Reliv Classic, Reliv Now, Innergize!, and FibRestore along with LunaRich X capsules. The company markets and sells its products through a direct selling system of independent distributors in the United States, Australia, Austria, Canada, France, Germany, Indonesia, Ireland, Malaysia, Mexico, the Netherlands, New Zealand, the Philippines, and the United Kingdom. Reliv' International, Inc. was founded in 1988 and is headquartered in Chesterfield, Missouri.
Acerus Pharmaceuticals logo

Acerus Pharmaceuticals

OTCMKTS:TRLPF
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.